Rafael Starts Mid-Stage Biliary Tract Cancer Trial With CPI-613 Combo Regime

Rafael Pharmaceuticals Inc RFL has completed a Phase 1b trial of CPI-613 (devimistat) combined with gemcitabine and cisplatin in patients with biliary tract cancer.
In collaboration with Michigan Medicine, the Phase 1b study consisted of a multicenter trial of devimistat combo regime as first-line therapy for locally advanced unresectable or metastatic biliary tract cancer who have had no prior treatment.
The 2:1 randomized Phase 2 part of the trial has already started enrollment and will now determine the efficacy of devimistat at this maximum tolerated dose combined with gemcitabine and cisplatin.
An estimated 68 to 78 patients will be enrolled in the study.
Price Action: RFL shares are up 10.9% at $42.37 during the market session on the last check Wednesday.

Posted In:

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.